# US 2001/0036937 A1 · Treatment of ICU-associated hypocalcemia with vitamin D compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0036937 A1
- Document ID: US20010036937A1
- Status: Published application
- Kind: A1
- Application number: 09/827,495
- Filed: 2001-04-06
- Published: 2001-11-01
- Earliest claimed: 2000-04-07
- Inventors: Leticia Delgado-Herrera; Patricia Loreen Mershimer; Richard Zager
- Web page: https://patentgrep.com/patent/US20010036937A1

## CPC

- A61K 31/593: 9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
- A61K 31/59: Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K 31/592: 9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
- A61P 3/02: Nutrients, e.g. vitamins, minerals
- A61P 19/00: Drugs for skeletal disorders
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a method of improving intensive care unit (ICU)-associated hypocalcemia in a mammal by the administration of a vitamin D compound, or other compounds exhibiting vitamin D-like activity, to the mammal for a sufficient period of time to improve or restore the serum calcium levels of the mammal.

## Claims

### Claim 1

A method for treating ICU-associated hypocalcemia in a mammal to restore or maintain ionized serum calcium in said mammal which comprises administering to said mammal a therapeutically effective amount of a vitamin D compound.

### Claim 2 (depends on 1)

The method of claim 1 wherein the vitamin D compound is selected from compound having Formula I.

### Claim 3 (depends on 1)

The method of claim 1 wherein the vitamin D compound is administered in an amount of from about 0.1 micrograms to about 2 milligrams per day depending upon the vitamin D compound administered.

### Claim 4 (depends on 1)

The method of claim 1 wherein the vitamin D compound is administered daily to said mammal for about 1-4 weeks.

### Claim 5 (depends on 1)

The method of claim 1 wherein the vitamin D compound is combined with a non-toxic pharmaceutically acceptable carrier prior to administration.

### Claim 6 (depends on 1)

The method of claim 1 wherein the vitamin D compound is vitamin D3 or a vitamin D3 derivative.

### Claim 7 (depends on 6)

The method of claim 6 wherein the vitamin D compound is 1,25-dihydroxy vitamin D3.

### Claim 8 (depends on 1)

The method of claim 1 wherein the vitamin D compound is vitamin D2 or a vitamin D2 derivative.

### Claim 9 (depends on 8)

The method of claim 8 wherein the vitamin D2 compound is 1,25-dihydroxy-19-nor ergocalciferol.
